NovoSeven® in warfarin-treated patients

被引：24

作者：

Berntorp, E

Stigendal, L

Lethagen, S

Olofsson, L

Hedner, U

机构：

[1] Univ Lund, Univ Hosp, Dept Coagulat Disorders, Malmo, Sweden

[2] Sahlgrens Univ Hosp, Dept Med, Haemophilia Ctr, S-41345 Gothenburg, Sweden

[3] Novo Nordisk AS, Hlth Care Discovery, DK-2820 Gentofte, Denmark

来源：

BLOOD COAGULATION & FIBRINOLYSIS | 2000年 / 11卷

关键词：

recombinant activated factor VII; rFVIIa; warfarin; haemorrhage; vitamin K-dependent proteins;

D O I：

10.1097/00001721-200004001-00021

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Haemorrhages represent a major complication of treatment with vitamin K antagonists. In cases of severe bleeding, a prompt effect on the increased International Normalized Ratio value is vital to achieve haemostasis. As conventional treatment, that is plasma or plasma-derived concentrates, carries the risk of blood-borne virus transmission, new treatments are needed. An open, multicentre pilot trial is currently under way to determine the effect of recombinant activated factor VII (rFVIIa; NovoSeven(R)) administered to patients experiencing a bleeding episode after receiving vitamin K antagonists. When rFVIIa was given to a patient with a warfarin-induced nosebleed, it had an immediate haemostatic effect and the International Normalized Ratio value virtually normalized. Blood Coagul Fibrinolysis 11 (suppl 1):S113-S115 (C) 2000 Lippincott Williams & Wilkins.

引用

页码：S113 / S115

页数：3

共 3 条

[1] The effect of recombinant factor VIIa (NovoSeven™) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0 [J].